Shionogi & Co., Ltd. (OTCMKTS:SGIOY) Hits New 52-Week High - What's Next?

Shionogi & Co., Ltd. (OTCMKTS:SGIOY - Get Free Report) shares hit a new 52-week high during trading on Tuesday . The company traded as high as $8.29 and last traded at $7.96, with a volume of 150683 shares changing hands. The stock had previously closed at $7.78.

Shionogi & Co., Ltd. Stock Performance

The firm has a market cap of $14.09 billion, a PE ratio of 13.86, a PEG ratio of 2.37 and a beta of 0.21. The company has a quick ratio of 7.01, a current ratio of 7.64 and a debt-to-equity ratio of 0.01. The company has a 50-day simple moving average of $7.59 and a two-hundred day simple moving average of $7.21.

Shionogi & Co., Ltd. (OTCMKTS:SGIOY - Get Free Report) last announced its quarterly earnings data on Friday, January 31st. The company reported $0.16 EPS for the quarter. Shionogi & Co., Ltd. had a net margin of 35.53% and a return on equity of 12.02%. As a group, equities research analysts forecast that Shionogi & Co., Ltd. will post 0.66 earnings per share for the current year.

Shionogi & Co., Ltd. Company Profile

Shionogi & Co, Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug.